# Bispecific Antibody-Based Salvage Therapy Followed by CAR-T ± ASCT in R/R Aggressive B-Cell Lymphoma

> **NCT06996132** · PHASE2 · RECRUITING · sponsor: **Institute of Hematology & Blood Diseases Hospital, China** · enrollment: 25 (estimated)

## Conditions studied

- Relapsed or Refractory Aggressive B-cell Lymphoma

## Interventions

- **DRUG:** Glofitamab
- **DRUG:** Chimeric Antigen Receptor T Cells (CAR-T)

## Key facts

- **NCT ID:** NCT06996132
- **Lead sponsor:** Institute of Hematology & Blood Diseases Hospital, China
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-05-09
- **Primary completion:** 2027-05-30
- **Final completion:** 2027-12-30
- **Target enrollment:** 25 (ESTIMATED)
- **Last updated:** 2025-06-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06996132

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06996132, "Bispecific Antibody-Based Salvage Therapy Followed by CAR-T ± ASCT in R/R Aggressive B-Cell Lymphoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06996132. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*